Conduit Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: CDTTW · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
Conduit Pharma (CTPH) filed an 8-K detailing a material agreement and equity sales.
AI Summary
Conduit Pharmaceuticals Inc. announced on June 3, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities and provided a Regulation FD disclosure. This 8-K filing includes financial statements and exhibits.
Why It Matters
This filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material agreements and unregistered equity sales, which can introduce financial and regulatory risks.
Key Numbers
- 11.50 — Warrant Exercise Price (Details on redeemable warrants associated with equity sales.)
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Murphy Canyon Acquisition Corp. (company) — Former company name
- June 3, 2025 (date) — Date of earliest event reported
- 001-41245 (other) — SEC File Number
- 87-3272543 (other) — EIN
FAQ
What is the nature of the material definitive agreement entered into by Conduit Pharmaceuticals Inc.?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before June 3, 2025.
What type of equity securities were sold unregistered?
The filing mentions 'CommonStock' and 'RedeemableWarrants' as types of equity securities involved in unregistered sales.
When was Conduit Pharmaceuticals Inc. formerly known as Murphy Canyon Acquisition Corp.?
The date of the name change from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc. was November 30, 2021.
What is the exercise price for the redeemable warrants mentioned in the filing?
The exercise price for the redeemable warrants is $11.50 per share.
What is the SIC code for Conduit Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Conduit Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding CONDUIT PHARMACEUTICALS INC. (CDTTW).